Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology
Ken KatoYuko Kitagawa


Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in patients with previously treated advanced oesophageal squamous cell carcinoma. We did a multicentre, randomised, open-label, phase 3 trial (ATTRACTION-3) at 90 hospitals and cancer centres in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK, and the USA. We enrolled patients aged 20 years and older with unresectable advanced or recurrent oesophageal squamous cell carcinoma (regardless of PD-L1 expression), at least one measurable or non-measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, a baseline Eastern Cooperative Oncology Group performance status of 0-1, and who were refractory or intolerant to one previous fluoropyrimidine-based and platinum-based chemotherapy and had a life expectancy of at least 3 months. Patients were randomly assigned (1:1) to either nivolumab (240 mg for 30 min every 2 weeks) or investigator's choice of chemotherapy (paclitaxel 100 mg/m2 for at least 60 min once per week for 6 weeks then 1 week off; or docetaxel 75 mg/m2 f...Continue Reading


Oct 30, 2019·Nature Reviews. Gastroenterology & Hepatology·Isobel Leake
Feb 6, 2020·Cancers·Hannah Christina PuhrAysegül Ilhan-Mutlu
Mar 4, 2020·International Journal of Molecular Sciences·Caterina VivaldiLorenzo Fornaro
Feb 19, 2020·Expert Review of Molecular Diagnostics·Nicolas Zhou, Wayne L Hofstetter
Jun 18, 2020·Oncotarget·Anders Handrup KvernelandInge Marie Svane
Jul 6, 2020·Expert Opinion on Biological Therapy·Shun Yamamoto, Ken Kato
Aug 22, 2020·Expert Review of Anticancer Therapy·Hiroshi Imazeki, Ken Kato
Jun 12, 2020·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Masahiro OgasawaraShuichi Ota
Mar 27, 2020·Immunotherapy·Dimitrios SchizasTheodore Liakakos
Jun 26, 2020·Frontiers in Oncology·Robert PowerMargaret R Dunne
Oct 17, 2019·Nature Reviews. Clinical Oncology·Diana Romero
May 13, 2020·Journal for Immunotherapy of Cancer·Alberto PucciniMohamed E Salem
Jul 30, 2020·Annals of Gastroenterological Surgery·Kohei YamashitaHideo Baba
Jun 6, 2020·Frontiers in Oncology·Raghav SundarPatrick Tan
Jan 29, 2020·World Journal of Gastroenterology : WJG·Takumi OnoyamaHajime Isomoto
Aug 18, 2020·Current Oncology Reports·Gretel Terrero, A Craig Lockhart
Aug 5, 2020·Journal of Gastroenterology·Fiona TurkesNaureen Starling
Jul 2, 2020·Cancer Management and Research·Keitaro ShimozakiTakanori Kanai
Sep 24, 2020·Esophagus : Official Journal of the Japan Esophageal Society·Yoshihiro KakejiSatoshi Suzuki
Jul 18, 2020·CNS Neuroscience & Therapeutics·Hao XuNanxiang Xiong
Sep 23, 2020·British Journal of Cancer·Mark A BaxterRussell D Petty
Oct 3, 2020·Annals of Gastroenterological Surgery·Hiroshi SaekiKen Shirabe
Aug 13, 2020·Journal of Clinical Medicine·Anita MazloomUqba Khan
Aug 15, 2020·The Korean Journal of Thoracic and Cardiovascular Surgery·Jong-Mu Sun
Aug 12, 2020·Future Oncology·Shun Yamamoto, Ken Kato
Aug 14, 2020·Journal of Hematology & Oncology·Basit SalikKyohei Nakamura
Oct 8, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takashi KojimaUNKNOWN KEYNOTE-181 Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds


Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.